Long‐term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate‐polyglutamate 3
Fundamental & Clinical Pharmacology · 2025
DOI: 10.1111/fcp.13050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Jean Escal und 9 weiteren Autor:innen. Beteiligte Einrichtung: CHU Saint-Etienne, Laboratoire de Pharmacologie et Toxicologie, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Université Jean Monnet Saint-Étienne, S…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Methotrexate, Erythrocytes, Polyglutamic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nordic Pharma Group, Nordic Pharma.
Abstract (Originalsprache)
Background
Methotrexate (MTX) is the first‐line treatment for Rheumatoid Arthritis (RA), yet 30%–50% of RA patients develop resistance to MTX, which can manifest several years after treatment initiation.
Objective
This study investigates the relationship between erythrocyte methotrexate polyglutamates (MTX‐PGs) subtype concentrations and clinical disease activity in RA patients undergoing long‐term MTX treatment.
Methods
In this cross‐sectional study, patients on a stable dose of subcutaneous MTX for several years were included. The study protocol was registered in the European Medicines Agency's clinical trials register (n°2017‐004348‐39). Patients were classified as either in clinical remission (DAS28 3.2). Erythrocyte MTX‐PGs concentrations were measured using liquid chromatography coupled with mass spectrometry. Multivariate logistic regression analysis assessed the probability of remission status based on MTX‐PG3 concentrations.
Results
The study included 34 patients with active RA and 25 in remission. The remission group had a median MTX treatment duration of 6.4 years compared to 2.6 years for the active group ( p = 0.001). Patients in remission had a longer median disease duration ( p = 0.02) and a lower Body Mass Index (BMI) ( p = 0.03) than those with active RA. A positive correlation was found between remission status and high MTX‐PG3 concentrations in patients with a BMI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CHU Saint-Etienne, Laboratoire de Pharmacologie et Toxicologie, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Université Jean Monnet Saint-Étienne, Saint-Etienne, France.
- CHU Saint-Étienne, Service de Rhumatologie, Saint-Etienne, France.
- Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Université Jean Monnet Saint-Étienne, Saint-Etienne, France.
- CHU Saint-Étienne, Service de Rhumatologie, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Université Jean Monnet Saint-Étienne, Saint-Etienne, France.
ORCID-Profile: Jean Escal
Förderung
- Nordic Pharma Group
- Nordic Pharma
Zitieren
APA
Escal, J., Poudret, M., Hodin, S., Neel, T., Coman, I., Locrelle, H., Amouzougan, A., Thomas, T., Delavenne, X., & Marotte, H. (2025). Long‐term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate‐polyglutamate 3. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.13050
Vancouver
Escal J, Poudret M, Hodin S, Neel T, Coman I, Locrelle H, et al. Long‐term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate‐polyglutamate 3. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.13050
BibTeX
@article{Escal2025,
author = {Escal, Jean and Poudret, Marion and Hodin, Sophie and Neel, Tiphany and Coman, Irina and Locrelle, Hervé and Amouzougan, Adamah and Thomas, Thierry and Delavenne, Xavier and Marotte, Hubert},
title = {Long‐term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate‐polyglutamate 3},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
doi = {10.1111/fcp.13050}
}
EUVIMED